EUVIMEDEUVIMED entdecken
MetaanalyseVergleichsstudie

Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis

Marliese Alexander iD, Kim Jachno, Kelly-Anne Phillips, John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam

Journal of Oncology Pharmacy Practice · 2024

DOI: 10.1177/10781552231180875 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Marliese Alexander und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Austr…. Hauptthemen laut MEDLINE: Rituximab, Trastuzumab, Administration, Intravenous. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Investigation of infection risk with subcutaneous versus intravenous trastuzumab and rituximab administration in an individual patient data (IPD) and published data meta-analysis of randomised controlled trials (RCTs).

Methods

Databases were searched to September 2021. Primary outcomes were serious and high-grade infection. Relative-risk (RR) and 95% confidence intervals (95%CI) were calculated using random-effects models.

Results

IPD meta-analysis (6 RCTs, 2971 participants, 2320 infections) demonstrated higher infection incidence with subcutaneous versus intravenous administration, without reaching statistical significance (serious: 12.2% versus 9.3%, RR 1.28, 95%CI 0.93to1.77, P = 0.13; high-grade: 12.2% versus 9.9%, RR 1.32, 95%CI 0.98to1.77, P = 0.07). With exclusion of an outlying study in post-hoc analysis, increased risks were statistically significant (serious: 13.1% versus 8.4%, RR 1.53, 95%CI 1.14to2.06, P = 0.01; high-grade: 13.2% versus 9.3%, RR 1.56, 95%CI 1.16to2.11, P < 0.01). Published data meta-analysis (8 RCTs, 3745 participants, 648 infections) demonstrated higher incidence of serious (HR 1.31, 95%CI 1.02to1.68, P = 0.04) and high-grade (HR 1.52, 95%CI 1.17to1.98, P < 0.01) infection with subcutaneous versus intravenous administration.

Conclusions

Results suggest increased infection risk with subcutaneous versus intravenous administration, although IPD findings are sensitive to exclusion of one trial with inconsistent results and identified risk-of-bias. Ongoing trials may confirm findings. Clinical surveillance should be considered when switching to subcutaneous administration. PROSPERO registration CRD42020221866/CRD42020125376.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabTrastuzumabAdministration, IntravenousHumansInjections, SubcutaneousAntineoplastic Agents, ImmunologicalInfectionsRandomized Controlled Trials as TopicNeoplasmsIncidence

Stichwörter der Autor:innen

Monoclonal antibodyinfectionrituximabsubcutaneoustrastuzuamb

Substanzen

RituximabTrastuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Pharmacy Department, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Department of Infectious Diseases, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

ORCID-Profile: Marliese Alexander

Zitieren

APA

Alexander, M., Jachno, K., Phillips, K. A., Seymour, J. F., Slavin, M. A., Cheung, A., Shen, V., Maarouf, D., Wolfe, R., & Lingaratnam, S. (2024). Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231180875

Vancouver

Alexander M, Jachno K, Phillips KA, Seymour JF, Slavin MA, Cheung A, et al. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231180875

BibTeX
@article{Alexander2024,
  author = {Alexander, Marliese and Jachno, Kim and Phillips, Kelly-Anne and Seymour, John F and Slavin, Monica A and Cheung, Ada and Shen, Vivian and Maarouf, Dana and Wolfe, Rory and Lingaratnam, Senthil},
  title = {Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2024},
  doi = {10.1177/10781552231180875}
}
Kostenlos starten →